{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:35:59Z","timestamp":1769862959305,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SARS-CoV-2 infected patients between January 2020 and December 2021 treated with RDV were matched 1:1 to controls considering sociodemographics, comorbidities and clinical status. Multiple imputations were used to account for missing data. Effects on fatal outcome were estimated using uni- and multivariable Cox regression models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 9,687 patients. For those starting RDV administration in the complicated phase, Cox regression for fatal outcome showed an adjusted hazard ratio (aHR) of 0.59 (95%CI 0.41\u20130.83). Positive trends could be obtained for further scenarios: an aHR of 0.51 (95%CI 0.16\u20131.68) when RDV was initiated in uncomplicated and of 0.76 (95% CI 0.55\u20131.04) in a critical phase of disease. Patients receiving RDV with concomitant steroids exhibited a further reduction in aHR in both, the complicated (aHR 0.50, 95%CI 0.29\u20130.88) and critical phase (aHR 0.63, 95%CI 0.39\u20131.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study results elucidate that RDV use, in particular when initiated in the complicated phase and accompanied by steroids is associated with improved mortality. However, given the limitations of non-randomized trials in estimating the magnitude of the benefit of an intervention, further randomized trials focusing on the timing of therapy initiation seem warranted.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-01994-0","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T19:43:20Z","timestamp":1676058200000},"page":"1033-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study"],"prefix":"10.1007","volume":"51","author":[{"given":"Lisa","family":"Pilgram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina S.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Ruethrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin E. M.","family":"Koll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana M. Nunes","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hanses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Haselberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Vom Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timm","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"1994_CR1","unstructured":"International Labour Organization (ILO). ILO Monitor: COVID-19 and the world of work. Eighth edition. Updated estimates and analysis."},{"key":"1994_CR2","unstructured":"World Health Organization (WHO). Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (18.11.2022, date Last Accessed)."},{"key":"1994_CR3","unstructured":"Our World in Data. COVID-19 vaccinations, https:\/\/ourworldindata.org\/covid-vaccinations (18.11.2022, date Last Accessed)."},{"key":"1994_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00443-4","volume":"9","author":"TK Burki","year":"2021","unstructured":"Burki TK. The race between vaccination and evolution of COVID-19 variants. Lancet Respir Med. 2021;9: e109. https:\/\/doi.org\/10.1016\/S2213-2600(21)00443-4.","journal-title":"Lancet Respir Med"},{"key":"1994_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0892","author":"SB Omer","year":"2022","unstructured":"Omer SB, Malani PN. Booster vaccination to prevent COVID-19 in the era of omicron: an effective part of a layered public health approach. JAMA. 2022. https:\/\/doi.org\/10.1001\/jama.2022.0892.","journal-title":"JAMA"},{"key":"1994_CR6","doi-asserted-by":"publisher","first-page":"m3862","DOI":"10.1136\/bmj.m3862","volume":"371","author":"M Cevik","year":"2020","unstructured":"Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. https:\/\/doi.org\/10.1136\/bmj.m3862.","journal-title":"BMJ"},{"key":"1994_CR7","doi-asserted-by":"publisher","unstructured":"Ansems K et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8: CD014962 https:\/\/doi.org\/10.1002\/14651858.CD014962","DOI":"10.1002\/14651858.CD014962"},{"key":"1994_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2107934.","journal-title":"N Engl J Med"},{"key":"1994_CR9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2118542.","journal-title":"N Engl J Med"},{"key":"1994_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","author":"A Jayk Bernal","year":"2021","unstructured":"Jayk Bernal A, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2116044.","journal-title":"N Engl J Med"},{"key":"1994_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021;385: e81. https:\/\/doi.org\/10.1056\/NEJMoa2108163.","journal-title":"N Engl J Med"},{"key":"1994_CR12","doi-asserted-by":"publisher","unstructured":"Wagner C et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8:CD014963, https:\/\/doi.org\/10.1002\/14651858.CD014963","DOI":"10.1002\/14651858.CD014963"},{"key":"1994_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"The Recovery Collaborative Group","year":"2021","unstructured":"The Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0.","journal-title":"Lancet"},{"key":"1994_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407\u201318. https:\/\/doi.org\/10.1016\/S2213-2600(21)00331-3.","journal-title":"Lancet Respir Med"},{"key":"1994_CR15","unstructured":"U.S. Food and Drug Administration (FDA). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 (18.11.2022, Date Last Accessed)."},{"key":"1994_CR16","unstructured":"European Medicines Agency (EMA). Veklury - remdesivir, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury (18.11.2022, Date Last Accessed)."},{"key":"1994_CR17","doi-asserted-by":"publisher","first-page":"m3379","DOI":"10.1136\/bmj.m3379","volume":"370","author":"B Rochwerg","year":"2020","unstructured":"Rochwerg B, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. https:\/\/doi.org\/10.1136\/bmj.m3379.","journal-title":"BMJ"},{"key":"1994_CR18","unstructured":"Kluge S, Janssens U et al. S2k Leitlinie \u2013 Empfehlungen zur station\u00e4ren Therapie von Patienten mit COVID-19. (AWMF online. https:\/\/register.awmf.org\/assets\/ guidelines\/113\u2013001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022\u201309_1.pdf, 18.11.2022, Date Last Accessed)."},{"key":"1994_CR19","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, et al. Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med. 2020;383:1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"key":"1994_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2020","unstructured":"WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 \u2014 interim WHO solidarity trial results. N Engl J Med. 2020;384:497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184.","journal-title":"N Engl J Med"},{"key":"1994_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","volume":"22","author":"F Ader","year":"2022","unstructured":"Ader F, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22:209\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0.","journal-title":"Lancet Infect Dis"},{"key":"1994_CR22","unstructured":"European Medicines Agency (EMA). Patient registries, https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/patient-registries (18.11.2022, Date Last Accessed)."},{"key":"1994_CR23","unstructured":"European Network for Health Technology Assessment (EUnetHTA). Vision paper on the sustainable availability of the proposed Registry Evaluation and Quality Standards Tool (REQueST). (2019)."},{"key":"1994_CR24","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.phrs.2020.104899","volume":"158","author":"S Antinori","year":"2020","unstructured":"Antinori S, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899. https:\/\/doi.org\/10.1016\/j.phrs.2020.104899.","journal-title":"Pharmacol Res"},{"key":"1994_CR25","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382:2327\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2007016.","journal-title":"N Engl J Med"},{"key":"1994_CR26","doi-asserted-by":"publisher","unstructured":"Russo A et al. Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. J Clin Med 2021 10.https:\/\/doi.org\/10.3390\/jcm10173784","DOI":"10.3390\/jcm10173784"},{"key":"1994_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/07357907.2020.1841922","volume":"38","author":"GH Lyman","year":"2020","unstructured":"Lyman GH, Kuderer NM. Randomized controlled trials versus real-world data in the COVID-19 era: a false narrative. Cancer Invest. 2020;38:537\u201342. https:\/\/doi.org\/10.1080\/07357907.2020.1841922.","journal-title":"Cancer Invest"},{"key":"1994_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cmi.2021.03.003","volume":"27","author":"O Martinuka","year":"2021","unstructured":"Martinuka O, von Cube M, Wolkewitz M. Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness. Clin Microbiol Infect. 2021;27:949\u201357. https:\/\/doi.org\/10.1016\/j.cmi.2021.03.003.","journal-title":"Clin Microbiol Infect"},{"key":"1994_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01826-7","author":"L Pilgram","year":"2022","unstructured":"Pilgram L, et al. SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). Infection. 2022. https:\/\/doi.org\/10.1007\/s15010-022-01826-7.","journal-title":"Infection"},{"key":"1994_CR30","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1055\/a-1655-8705","volume":"83","author":"L Pilgram","year":"2021","unstructured":"Pilgram L, et al. The COVID-19 pandemic as an opportunity and challenge for registries in health services research: lessons learned from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS). Gesundheitswesen. 2021;83:S45\u201353. https:\/\/doi.org\/10.1055\/a-1655-8705.","journal-title":"Gesundheitswesen"},{"key":"1994_CR31","unstructured":"The LEOSS study group. LEOSS metadata on medical data models (mdm) portal., 2021. https:\/\/medical-data-models.org\/42476 (18.11.2022, Date Last Accessed)."},{"key":"1994_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41597-020-00773-y","volume":"7","author":"CEM Jakob","year":"2020","unstructured":"Jakob CEM, Kohlmayer F, Meurers T, Vehreschild JJ, Prasser F. Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. Sci Data. 2020;7:435. https:\/\/doi.org\/10.1038\/s41597-020-00773-y.","journal-title":"Sci Data"},{"key":"1994_CR33","unstructured":"R Core Team. R Foundation for Statistical Computing. (Vienna, Austria, 2020)."},{"key":"1994_CR34","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. https:\/\/doi.org\/10.1136\/bmj.b2393.","journal-title":"BMJ"},{"key":"1994_CR35","unstructured":"Van Buuren SG-O, Karin V, Gerko V, Schouten R et al. Multivariate Imputation by Chained Equations, https:\/\/cran.r-project.org\/web\/packages\/ mice\/mice.pdf (18.11.2022, Date Last Accessed)"},{"key":"1994_CR36","unstructured":"U.S. Food and Drug Administration (FDA). Veklury: Highlights of prescribing information. (2020)."},{"key":"1994_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3071","volume":"4","author":"BT Garibaldi","year":"2021","unstructured":"Garibaldi BT, et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA Netw Open. 2021;4: e213071. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3071.","journal-title":"JAMA Netw Open"},{"key":"1994_CR38","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","volume":"383","author":"JD Goldman","year":"2020","unstructured":"Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2015301.","journal-title":"N Engl J Med"},{"key":"1994_CR39","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(20)31022-9.","journal-title":"Lancet"},{"key":"1994_CR40","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1164\/rccm.201712-2371ED","volume":"197","author":"DS Hui","year":"2018","unstructured":"Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197:700\u20131. https:\/\/doi.org\/10.1164\/rccm.201712-2371ED.","journal-title":"Am J Respir Crit Care Med"},{"key":"1994_CR41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994.","journal-title":"N Engl J Med"},{"key":"1994_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-0037-1613749","volume":"83","author":"P Mismetti","year":"2000","unstructured":"Mismetti P, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14\u20139.","journal-title":"Thromb Haemost"},{"key":"1994_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0140-6736(21)02503-4","volume":"399","author":"CA Bradbury","year":"2022","unstructured":"Bradbury CA, McQuilten Z. Anticoagulation in COVID-19. Lancet. 2022;399:5\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(21)02503-4.","journal-title":"Lancet"},{"key":"1994_CR44","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048\u201357. https:\/\/doi.org\/10.1001\/jama.2020.16349.","journal-title":"JAMA"},{"key":"1994_CR45","unstructured":"World Health Organization (WHO). Novel Coronavirus COVID-19 Therapeutic Trial Synopsis. (2020)."},{"key":"1994_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:853\u201362. https:\/\/doi.org\/10.1016\/S2213-2600(20)30316-7.","journal-title":"Lancet Respir Med"},{"key":"1994_CR47","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cmi.2020.08.011","volume":"26","author":"I Nachtigall","year":"2020","unstructured":"Nachtigall I, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect. 2020;26:1663\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2020.08.011.","journal-title":"Clin Microbiol Infect"},{"key":"1994_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271822","volume":"17","author":"C Raichle","year":"2022","unstructured":"Raichle C, et al. Hospitalized patients dying with SARS-CoV-2 infection-An analysis of patient characteristics and management in ICU and general ward of the LEOSS registry. PLoS One. 2022;17: e0271822. https:\/\/doi.org\/10.1371\/journal.pone.0271822.","journal-title":"PLoS One"},{"key":"1994_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/v13060963","author":"L Dolken","year":"2021","unstructured":"Dolken L, Stich A, Spinner CD. Remdesivir for early COVID-19 treatment of high-risk individuals prior to or at early disease onset-lessons learned. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13060963.","journal-title":"Viruses"},{"key":"1994_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2116846.","journal-title":"N Engl J Med"},{"key":"1994_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac256","author":"N Piccicacco","year":"2022","unstructured":"Piccicacco N, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother. 2022. https:\/\/doi.org\/10.1093\/jac\/dkac256.","journal-title":"J Antimicrob Chemother"},{"key":"1994_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","author":"LA VanBlargan","year":"2022","unstructured":"VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.15.29 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-021-01678-y.","journal-title":"Nat Med"},{"key":"1994_CR53","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel L, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105252.","journal-title":"Antiviral Res"},{"key":"1994_CR54","unstructured":"European Medicines Agency (EMA). COVID-19 treatments, https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-treatments (18.11.2022, Date Last Accessed)."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-01994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T19:08:37Z","timestamp":1689620917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-01994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-01994-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.H. received fees for presentations and lectures for the German Society for Interdisciplinary Emergency and Acute Medicine (DGINA) and the German Academy of Infectious Diseases, and has participated in several advisory boards. M.H. reported grants and honoraria from ViiV Healthcare, further honoraria from THERA technologies and MSD. B.J. received honoraria for lectures and participation in an HIV advisory board from Gilead. L.P. reported grants to the institution in the context of the indicated funding of LEOSS and is a participant in the BIH Charit\u00e9 Junior Digital Clinician Scientist Program funded by the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, and the Berlin Institute of Health at Charit\u00e9 (BIH). M.R. declared support for attending meetings and\/or travel by Janssen Germany. C.S. received grants, consulting fees, support for attending meetings and honoraria from AbbVie, Gilead, Janssen, Cepheid, MSD, ViiV Healthcare, Eli Lilly, B. Braun Melsungen, Formycon, SOBI and Apeiron. J.V. indicated honoraria from MSD, Gilead, Pfizer, Astellas Pharma, Basilea, Shionogi, Molecular Health, Janssen, NordForsk, Back Bay Strategies, the German Centre for Infection Research (DZIF), the German Academy of Infectious Diseases, the German Society for Infectious Diseases (DGI), the German Society for Internal Medicine (DGIM), the Medical Association of North Rhine, the University Hospital Aachen, University Hospital Freiburg, University Manchester and the German Network of University Medicine (NUM), as well as participation on advisory boards by Pfizer, Gilead and Shionogi and further research funding by the German Federal Ministry of Education and Research (BMBF), University of Bristol and the Rigshospitalet Copenhagen. M.V. received grants from Astellas Pharma, Basilea, Gilead Sciences, MSD, Organobalance, Pfizer, 3\u00a0M, Biontech, DaVolterra, Evonik, Glycom, Immunic, MaaTPharma, Seres Tehrapeutics and Takeda Pharmaceutical, as well as consulting fees from Alb Fils Kliniken GmbH, Srederypharm, Farmak, Intern, Holding, Ferring, SocraTec R&D, Arderypharm, Astellas Pharma, DaVolterra, Ferring, Immunic AG, MaaTPharma and MSD. All disclosures are reported to be outside the submitted work. The authors declare no conflicts of interest. All other authors: none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. Due to the doubly anonymized data [] and the retrospective character, an informed consent was not mandatory. Approval for LEOSS was first obtained at our ethics committee of the University Hospital Frankfurt and the University Hospital Cologne, applicable local ethics committees of further participating centres joined the vote. A complete list can be found on the LEOSS website (). LEOSS is registered at the German Clinical Trials Register (DRKS, No. S00021145).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}